Wyeth and Catalyst Biosciences, Inc. have formed an exclusive worldwide collaboration for the discovery, development and commercialization of Factor VIIa products to treat hemophilia and other bleeding conditions. Total payments under the collaboration could exceed $500 million and include an upfront payment of $21 million, research funding and milestone payments. Wyeth will fund the discovery, research and preclinical development by Catalyst of Factor VIIa products, including Catalyst’...